• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝静脉流出道梗阻患者肝细胞癌的发病率及危险因素

Incidence and risk factors of hepatocellular carcinoma in patients with hepatic venous outflow tract obstruction.

作者信息

Paul S B, Sreenivas V, Gamanagatti S R, Sharma H, Dhamija E, Acharya S K

机构信息

Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi, India.

出版信息

Aliment Pharmacol Ther. 2015 May;41(10):961-71. doi: 10.1111/apt.13173. Epub 2015 Mar 23.

DOI:10.1111/apt.13173
PMID:25809735
Abstract

BACKGROUND

Frequency of hepatocellular carcinoma (HCC) in hepatic venous outflow tract obstruction (HVOTO) is unclear and risk factors in HVOTO associated with HCC are unknown.

AIM

To assess the incidence of HCC and to identify risk factors for HCC in primary HVOTO.

METHODS

In the consecutive primary HVOTO patients evaluated between 1989 to 2013, the incidence of HCC among HVOTO was assessed in a retrospective cohort study and identification of the risk factors for HCC in HVOTO patients done by a case-control study.

RESULTS

Of the 421 HVOTO patients, 8 had HCC at presentation (prevalence 1.9%). Another 8 of the remaining 413 developed HCC during 2076.2 person-years follow-up (mean 5.03 + 4.65 years, range 0.08-20 years). The cumulative incidence of HCC was 3.5% (95% CI 1.28-9.2%) at 10 years. The case-control study included 16 HCC as cases and remaining 405 as controls. Controls were predominantly males (M:F - 230:175), mean age 29 ± 10.3 years. Cases were predominantly females with an older age of 36.2 ± 11.4 years (P < 0.01, OR = 1.06, CI 1.0-1.10%). Presence of cirrhosis (P < 0.001), combined inferior vena cava (IVC) and hepatic vein (HV) block (P < 0.03, OR = 5.58, CI 1.43-25.30%) and long-segment IVC block (P < 0.02, OR = 6.50, CI 1.32-32.0%) were significantly higher among cases than controls.

CONCLUSIONS

Hepatic venous outflow tract obstruction is a risk factor for HCC. The cumulative incidence of HCC in HVOTO is low and progressively increases over time. Those with liver cirrhosis, combined IVC and HV block and long-segment IVC block are at risk to develop HCC and need active surveillance.

摘要

背景

肝静脉流出道梗阻(HVOTO)患者中肝细胞癌(HCC)的发生率尚不清楚,且HVOTO中与HCC相关的危险因素也未知。

目的

评估原发性HVOTO中HCC的发生率,并确定其危险因素。

方法

在1989年至2013年期间评估的连续性原发性HVOTO患者中,通过回顾性队列研究评估HVOTO中HCC的发生率,并通过病例对照研究确定HVOTO患者中HCC的危险因素。

结果

在421例HVOTO患者中,8例在就诊时患有HCC(患病率1.9%)。在其余413例患者中,另外8例在2076.2人年的随访期间(平均5.03±4.65年,范围0.08 - 20年)发生了HCC。10年时HCC的累积发生率为3.5%(95%CI 1.28 - 9.2%)。病例对照研究包括16例HCC患者作为病例,其余405例作为对照。对照主要为男性(男:女 = 230:175),平均年龄29±10.3岁。病例主要为女性,年龄较大,为36.2±11.4岁(P < 0.01,OR = 1.06,CI 1.0 - 1.10%)。病例组中肝硬化的存在(P < 0.001)、下腔静脉(IVC)和肝静脉(HV)联合阻塞(P < 0.03,OR = 5.58,CI 1.43 - 25.30%)以及长段IVC阻塞(P < 0.02,OR = 6.50,CI 1.32 - 32.0%)显著高于对照组。

结论

肝静脉流出道梗阻是HCC的一个危险因素。HVOTO中HCC的累积发生率较低,但随时间逐渐增加。患有肝硬化、IVC和HV联合阻塞以及长段IVC阻塞的患者有发生HCC的风险,需要进行积极监测。

相似文献

1
Incidence and risk factors of hepatocellular carcinoma in patients with hepatic venous outflow tract obstruction.肝静脉流出道梗阻患者肝细胞癌的发病率及危险因素
Aliment Pharmacol Ther. 2015 May;41(10):961-71. doi: 10.1111/apt.13173. Epub 2015 Mar 23.
2
Clinical features and etiology of hepatocellular carcinoma arising in patients with membranous obstruction of the inferior vena cava: in reference to hepatitis viral infection.下腔静脉膜性梗阻患者发生肝细胞癌的临床特征及病因:关于病毒性肝炎感染
J Gastroenterol Hepatol. 2000 Oct;15(10):1205-11. doi: 10.1046/j.1440-1746.2000.02303.x.
3
Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review.布加综合征患者中肝细胞癌的患病率及危险因素:系统综述。
Eur J Gastroenterol Hepatol. 2013 Jul;25(7):830-41. doi: 10.1097/MEG.0b013e32835eb8d4.
4
Budd-Chiari syndrome/hepatic venous outflow tract obstruction.布加综合征/肝静脉流出道梗阻。
Hepatol Int. 2018 Feb;12(Suppl 1):168-180. doi: 10.1007/s12072-017-9810-5. Epub 2017 Jul 6.
5
Does hepatic vein outflow obstruction contribute to the pathogenesis of hepatocellular carcinoma?肝静脉流出道梗阻是否参与肝细胞癌的发病机制?
J Clin Gastroenterol. 1998 Jul;27(1):67-71. doi: 10.1097/00004836-199807000-00014.
6
Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors.布加综合征中的肝细胞癌:特征与危险因素
Gut. 2008 Jun;57(6):828-35. doi: 10.1136/gut.2007.139477. Epub 2008 Jan 24.
7
High prevalence of hepatitis B virus infection and inferior vena cava obstruction among patients with liver cirrhosis or hepatocellular carcinoma in Nepal.尼泊尔肝硬化或肝细胞癌患者中乙肝病毒感染及下腔静脉阻塞的高患病率。
J Gastroenterol Hepatol. 2007 Nov;22(11):1921-8. doi: 10.1111/j.1440-1746.2006.04611.x.
8
Hepatic vein obstruction is the most common type of hepatic venous outflow obstruction regardless of socioeconomic status.无论社会经济状况如何,肝静脉阻塞都是肝静脉流出道阻塞最常见的类型。
Ann Gastroenterol. 2015 Jan-Mar;28(1):130-134.
9
Clinical and prothrombotic profile of hepatic vein outflow tract obstruction.肝静脉流出道梗阻的临床和血栓前状态
Indian J Pediatr. 2014 May;81(5):434-40. doi: 10.1007/s12098-013-1131-7. Epub 2013 Jul 25.
10
Hepatic venous outflow tract obstruction: treatment outcomes and development of a new prognostic score.肝静脉流出道梗阻:治疗结果及一种新的预后评分的制定
Aliment Pharmacol Ther. 2016 Jun;43(11):1154-67. doi: 10.1111/apt.13604. Epub 2016 Apr 7.

引用本文的文献

1
Role of Vascular Liver Diseases in Hepatocellular Carcinoma Development.血管性肝病在肝细胞癌发生中的作用。
Cancers (Basel). 2025 Jun 20;17(13):2060. doi: 10.3390/cancers17132060.
2
Next-Generation Sequencing Identifies Novel Germline Mutations in Patients with Budd-Chiari Syndrome-Associated Hepatocellular Carcinoma.下一代测序鉴定布加综合征相关肝细胞癌患者的新型种系突变。
Dig Dis Sci. 2025 May;70(5):1788-1798. doi: 10.1007/s10620-025-08942-y. Epub 2025 Feb 28.
3
Clinical profile and outcomes of hepatocellular carcinoma in primary Budd-Chiari syndrome.
原发性布加综合征合并肝细胞癌的临床特征及预后
World J Gastrointest Oncol. 2024 Mar 15;16(3):699-715. doi: 10.4251/wjgo.v16.i3.699.
4
Focal Liver Lesions in Budd-Chiari Syndrome: Spectrum of Imaging Findings.布加综合征的肝脏局灶性病变:影像学表现谱
Diagnostics (Basel). 2023 Jul 12;13(14):2346. doi: 10.3390/diagnostics13142346.
5
Management of splanchnic vein thrombosis.内脏静脉血栓形成的管理。
JHEP Rep. 2023 Jan 3;5(4):100667. doi: 10.1016/j.jhepr.2022.100667. eCollection 2023 Apr.
6
Budd-Chiari syndrome and its associated hepatocellular carcinoma: Clinical risk factors and potential immunotherapeutic benefit analysis.布加综合征及其相关肝细胞癌:临床危险因素及潜在免疫治疗获益分析
Front Oncol. 2022 Dec 8;12:1075685. doi: 10.3389/fonc.2022.1075685. eCollection 2022.
7
Budd-Chiari Syndrome Management: Controversies and Open Issues.布加综合征的管理:争议与未决问题
Diagnostics (Basel). 2022 Nov 3;12(11):2670. doi: 10.3390/diagnostics12112670.
8
Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).布加综合征:亚太肝病学会(APASL)的共识指南。
Hepatol Int. 2021 Jun;15(3):531-567. doi: 10.1007/s12072-021-10189-4. Epub 2021 Jul 8.
9
Epidemiology, pathogenesis, diagnosis, surveillance, and management of hepatocellular carcinoma associated with vascular liver disease.血管性肝病相关肝细胞癌的流行病学、发病机制、诊断、监测和管理。
Kaohsiung J Med Sci. 2021 May;37(5):355-360. doi: 10.1002/kjm2.12368. Epub 2021 Mar 2.
10
Budd Chiari Syndrome and Intrahepatic Cholangiocarcinoma, An Unusual Combination: Case Report and Review of the Literature.布加综合征与肝内胆管细胞癌的不常见组合:病例报告及文献复习。
Perm J. 2020 Nov;24:1-3. doi: 10.7812/TPP/19.204.